CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Evocalcet

依伏卡塞 杂质对照品Evocalcet Impurities

26 个杂质条目26 impurity entries

本页汇总 依伏卡塞 的 26 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 26 impurity reference standards of Evocalcet. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 依伏卡塞(Evocalcet)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesIsolation, synthesis, identification of new process-related impurities in evocalcet
    Journal of pharmaceutical and biomedical analysis · 2022 · Yan H et al.  ·  PMID 35278811  ·  DOI
  2. 分析方法Analytical MethodsQuantitative LC-MS/MS Assay for Evocalcet in Human Plasma: Comparative Pharmacokinetic Evaluation in Fasted and Fed Healthy Chinese Volunteers
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2026 · Chen K et al.  ·  PMID 41365185  ·  DOI

合成路线参考Reported synthetic routes

以下为公开文献中报道的合成方法(题录信息)。标题多已点明关键反应,可据此查阅原文了解完整路线与工艺条件。Published synthetic approaches. Titles usually name the key transformation; consult the original articles for full routes.

  • 合成方法SynthesisSpace-velocity-governed chemoselective pseudo-oxidation: a convergent flow platform for the synthesis of evocalcet
    RSC advances · 2026 · Tsubogo T et al.  ·  PMID 42712789  ·  DOI

依伏卡塞 —— 原料药与杂质对照品Evocalcet — drug substance & impurities

共 26 个条目(含原料药本体)26 items incl. the drug substance
Evocalcet Impurity 1 structure
1
依伏卡塞杂质1Evocalcet Impurity 1
Evocalcet Impurity 1
CAS No.1092366-92-1
Chemical FormulaC15H20N2O7S
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 2 structure
2
依伏卡塞杂质2Evocalcet Impurity 2
Evocalcet Impurity 2
CAS No.870964-69-5
Chemical FormulaC24H26N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 3 structure
3
依伏卡塞杂质3Evocalcet Impurity 3
Evocalcet Impurity 3
CAS No.870964-68-4
Chemical FormulaC24H26N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 4 structure
4
依伏卡塞杂质4Evocalcet Impurity 4
Evocalcet Impurity 4
CAS No.1666124-27-1
Chemical FormulaC16H20N2·C3H8O·2HCl
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 4 Dihydrochloride structure
4
伊万卡塞杂质4 双盐酸盐Evocalcet Impurity 4 Dihydrochloride
Evocalcet Impurity 4 Dihydrochloride
CAS No.870858-86-9
Chemical FormulaC16H20N2·2HCl
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 4 Monomer structure
4
伊万卡塞杂质4 单体Evocalcet Impurity 4 Monomer
Evocalcet Impurity 4 Monomer
CAS No.870966-25-9
Chemical FormulaC16H20N2
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 5 structure
5
依伏卡塞杂质5Evocalcet Impurity 5
Evocalcet Impurity 5
CAS No.870859-04-4
Chemical FormulaC21H28N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 7 (N-Nitroso Evocalcet) structure
7
依伏卡塞杂质7 (N-亚硝基依伏卡塞)Evocalcet Impurity 7 (N-Nitroso Evocalcet)
Evocalcet Impurity 7 (N-Nitroso Evocalcet)
CAS No.3051508-93-8
Chemical FormulaC24H25N3O3
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 9 structure
9
依伏卡塞杂质9Evocalcet Impurity 9
Evocalcet Impurity 9
CAS No.1666124-30-6
Chemical FormulaC26H30N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 12 structure
12
伊万卡塞杂质12Evocalcet Impurity 12
Evocalcet Impurity 12
CAS No.2851537-36-3
Chemical FormulaC32H32N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 13 structure
13
依伏卡塞杂质13Evocalcet Impurity 13
Evocalcet Impurity 13
CAS No.3054081-82-9
Chemical FormulaC32H32N2O4
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 14 structure
14
依伏卡塞杂质14Evocalcet Impurity 14
Evocalcet Impurity 14
CAS No.2851537-34-1
Chemical FormulaC20H19NO2
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 17 structure
17
依伏卡塞杂质17Evocalcet Impurity 17
Evocalcet Impurity 17
CAS No.870859-14-6
Chemical FormulaC23H24N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 19 structure
19
依伏卡塞杂质19Evocalcet Impurity 19
Evocalcet Impurity 19
CAS No.2381242-86-8
Chemical FormulaC14H25NO5
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 22 structure
22
伊万卡塞杂质22Evocalcet Impurity 22
Evocalcet Impurity 22
CAS No.26586-36-7
Chemical FormulaC12H15NO2
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 28 structure
28
依伏卡塞杂质28Evocalcet Impurity 28
Evocalcet Impurity 28
CAS No.2167323-88-6
Chemical FormulaC12H16N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 29 structure
29
依伏卡塞杂质29Evocalcet Impurity 29
Evocalcet Impurity 29
CAS No.1780151-22-5
Chemical FormulaC12H15NO3
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 30 structure
30
依伏卡塞杂质30Evocalcet Impurity 30
Evocalcet Impurity 30
CAS No.1039631-63-4
Chemical FormulaC21H28N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 34 structure
34
依伏卡塞杂质34Evocalcet Impurity 34
Evocalcet Impurity 34
CAS No.14062-25-0
Chemical FormulaC10H11BrO2
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 37 structure
37
依伏卡塞杂质37Evocalcet Impurity 37
Evocalcet Impurity 37
CAS No.2851537-33-0
Chemical FormulaC24H26N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 38 structure
38
依伏卡塞杂质38Evocalcet Impurity 38
Evocalcet Impurity 38
CAS No.2851537-35-2
Chemical FormulaC24H27N3O
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 41 structure
41
伊万卡塞杂质41Evocalcet Impurity 41
Evocalcet Impurity 41
CAS No.1956-40-7
Chemical FormulaC12H11NO
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 43 structure
43
伊万卡塞杂质43Evocalcet Impurity 43
Evocalcet Impurity 43
CAS No.1039631-66-7
Chemical FormulaC21H28N2O2
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 44 structure
44
依伏卡塞杂质44Evocalcet Impurity 44
Evocalcet Impurity 44
CAS No.946113-79-7
Chemical FormulaC24H23N
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 48 structure
48
伊万卡塞杂质48Evocalcet Impurity 48
Evocalcet Impurity 48
CAS No.15297-34-4
Chemical FormulaC13H13NO
Purity>95%询价On request
10mg25mg50mg100mg
Evocalcet Impurity 50 structure
50
伊万卡塞杂质50Evocalcet Impurity 50
Evocalcet Impurity 50
CAS No.74860-13-2
Chemical FormulaC8H8BrNO
Purity>95%询价On request
10mg25mg50mg100mg
本品种含亚硝胺类杂质条目。亚硝胺杂质属于 ICH M7 关注的潜在致突变杂质,建议在方法开发中纳入专属性考察。This list includes nitrosamine entries. Nitrosamines are potential mutagenic impurities under ICH M7 and should be covered by a specific method.

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

依伏卡塞 —— 研究文献与合成路线Evocalcet — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 依伏卡塞 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Evocalcet. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Isolation, synthesis, identification of new process-related impurities in evocalcet
    Yan H, Wang Y, Yue Y, et al. · Journal of pharmaceutical and biomedical analysis · 2022

合成路线文献Synthetic-route papers

  1. Space-velocity-governed chemoselective pseudo-oxidation: a convergent flow platform for the synthesis of evocalcet
    Tsubogo T, Sakamoto R, Ishitani H, et al. · RSC advances · 2026
  2. Isolation, synthesis, identification of new process-related impurities in evocalcet
    Yan H, Wang Y, Yue Y, et al. · Journal of pharmaceutical and biomedical analysis · 2022

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

依伏卡塞 杂质谱研究要点Evocalcet — impurity profiling notes

下面这些是拿到 依伏卡塞 的 26 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 26 impurity entries for Evocalcet, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances